News | February 25, 2025
Teva and Sanofi present new outcome from Phase 2b study of duvakitug
Findings to form the basis for a Phase 3 program, anticipated to start in H2 2025
Findings to form the basis for a Phase 3 program, anticipated to start in H2 2025
Aster commits to increase bed capacity in the State via capacity expansion and greenfield projects
Innovative chronic pain treatment receives IP protection in India's $55 billion pharmaceutical market
This Yearbook aims to distinguish those companies that have demonstrated strengths in corporate sustainability
The company will offer end-to-end services and solutions for the sector with a specific focus on sustainability
These results represent critical milestones for Philogen, as Fibromun has the potential to become second product to successfully complete multinational clinical trials with registration potential
The company will initially supply prototypes to diverse customers to evaluate in purification processes for producing gene therapy drugs with a view to swift commercialization
Antibe Therapeutics is a clinical-stage biotechnological company developing novel drugs primarily focusing on reducing pain and inflammation
Lilly plans to hire approximately more than 1,000 new highly-skilled team members
Nadda chairs Joint Strategy Meeting with Line Ministries for TB Mukt Bharat Abhiyan- 100-Day Intensified Campaign
Subscribe To Our Newsletter & Stay Updated
